Travis Brewer, vice president of payer relations at Texas Oncology, discusses the importance of oncologists’ collaboration with payers to improve value-based care.
Knowing the payer and knowing what they're willing to do to expand value-based care is crucial for improving cancer care, says Travis Brewer, vice president of payer relations, Texas Oncology. Brewer will appear at the Institute for Value-Based Medicine® June 8, 2023 event, held with The American Journal of Managed Care® and Texas Oncology.
Transcript
Why is collaboration between payers and oncology practices so important in providing patients with value-based care?
It all starts really with the payers and what they're willing to do from an expansion of access to value-based care. They really hold the purse strings.
It's also important to understand who the payer really is in this environment. In Texas, 70% or more of the commercial population that we see are self-funded plan sponsors; the employers are paying the bills versus a more traditional, fully insured model.
It really requires the payers willingness to put programs in place, but it also requires that the employers are on board with putting forward more quality focused, cost-effective, value-based models.
What are specific ways in which payers can collaborate with health care providers and oncology specialists to develop and implement value-based strategies in cancer care?
I think the key thing there is the provision of data, actionable data. A lot of the things that we are measured on in a lot of the value-based care models are things like hospital admission rates, presentation to emergency departments, the use of biosimilars where they're available in the chemo drug space, as well as generic prescribing, or prescribing of oral oncolytics in general.
Data from the health plans is very important, but it has to be actionable. It has to be something that we can take and bend some of the trend on, if you will; things that we can work with our local sites, our doctors, our nurse case managers, and all of the tools and resources that we bring to bear to help move the needle on some of the some of the value-based programs.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More